Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 8.55% is 76% above its 3-year average of 4.86%, near the high end of its 3-year range (0.00%–10.79%).
As of the fiscal period ended Wednesday, December 31, 2025. 5.26% below its 12-month average of 9.02%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
8.55%
RETURN ON EQUITY (ROE) AVG TTM
9.02%
RETURN ON EQUITY (ROE) AVG 3Y
4.86%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-5.26%
CURRENT VS 3Y AVG
+76.02%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-21.49%
vs the sector median at left
Market Cap
$32.40B
Return on Equity (ROE)
81.75%
TTM Avg
66.19%
3Y Avg
56.82%
5Y Avg
52.60%
Market Cap
$32.20B
Return on Equity (ROE)
38.14%
TTM Avg
28.93%
3Y Avg
25.01%
5Y Avg
22.95%
Market Cap
$30.74B
Return on Equity (ROE)
-22.60%
TTM Avg
-10.46%
3Y Avg
-1.37%
5Y Avg
1.10%
Market Cap
$30.72B
Return on Equity (ROE)
14.51%
TTM Avg
21.84%
3Y Avg
21.53%
5Y Avg
32.27%
Market Cap
$30.60B
Return on Equity (ROE)
23.41%
TTM Avg
22.23%
3Y Avg
22.34%
5Y Avg
21.79%
Market Cap
$29.99B
Return on Equity (ROE)
4.48%
TTM Avg
8.42%
3Y Avg
11.86%
5Y Avg
16.52%
Market Cap
$28.62B
Return on Equity (ROE)
24.67%
TTM Avg
-2178.82%
3Y Avg
-341.14%
5Y Avg
-117.12%
Market Cap
$38.68B
Return on Equity (ROE)
22.28%
TTM Avg
21.77%
3Y Avg
21.17%
5Y Avg
17.55%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medline Inc. (MDLN) | $33.22B | 8.55% | 9.02% | 4.86% | N/A |
| Zoetis Inc. (ZTS)vs › | $32.40B | 81.75% | 66.19% | 56.82% | 52.60% |
| DexCom, Inc. (DXCM)vs › | $32.20B | 38.14% | 28.93% | 25.01% | 22.95% |
| Centene Corp. (CNC)vs › | $30.74B | -22.60% | -10.46% | -1.37% | 1.10% |
| GE HealthCare Technologies Inc. (GEHC)vs › | $30.72B | 14.51% | 21.84% | 21.53% | 32.27% |
| ResMed Inc. (RMD)vs › | $30.60B | 23.41% | 22.23% | 22.34% | 21.79% |
| Biogen Inc. (BIIB)vs › | $29.99B | 4.48% | 8.42% | 11.86% | 16.52% |
| Mettler-Toledo International Inc. (MTD)vs › | $28.62B | 24.67% | -2178.82% | -341.14% | -117.12% |
| IQVIA Holdings Inc. (IQV)vs › | $38.68B | 22.28% | 21.77% | 21.17% | 17.55% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $27.44B | 59.67% | -187.43% | 134.89% | 51.69% |
ROE
8.6%
ROA
2.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 10.79% |
| 2024-12-31 | 7.26% |
| 2023-12-31 | 1.38% |
| 2022-12-31 | 0.00% |
